TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12460869
Drug: yohimbine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: yohimbine (3 mg IC)
Study: 7102537
Drug: Pindolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (5 mg four times a day)
Study: 12126265
Drug: Nebivolol 2.5-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 2.5-5 mg daily (n = 81)
Study: 12126265
Drug: Amlodipine 5-10
Normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5-10 mg daily (n = 87)
Study: 7697845
Drug: High-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aspirin (1000 mg/d)
Study: 1071668
Drug: Alprenolol (200-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprenolol (200-400 mg, twice daily)
Study: 22968811
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of both drugs
Study: 8216696
Drug: Clomipramine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (25 to 75 mg)
Study: 3549811
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% minoxidil
Study: 3549811
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil (1% and 5%)
Study: 19601782
Drug: PEG‐IFN (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN (1.5 mcg/Kg/w) plus RBV (>=10.6 mg/kg/d) for 24-48 or 48-72 weeks depending on genotype
Study: 17617285
Drug: Guanfacine extended-release
Normalized name: Guanfacine Extended-Release Tablets
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guanfacine extended-release (GXR) 1 mg
Study: 17617285
Drug: Guanfacine extended-release
Normalized name: Guanfacine Extended-Release Tablets
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guanfacine extended-release (GXR) 1 mg to 2 mg
Study: 17617285
Drug: Guanfacine extended-release
Normalized name: Guanfacine Extended-Release Tablets
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guanfacine extended-release (GXR) 1 mg to 4 mg
Study: 17617285
Drug: Guanfacine extended-release
Normalized name: Guanfacine Extended-Release Tablets
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guanfacine extended-release (GXR) 2 mg to 4 mg
Study: 17617285
Drug: Treatment-emergent adverse
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-emergent adverse events (AEs)
Study: 11075768
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of vitamin K orally
Study: 1358233
Drug: Thymoxamine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoxamine (80 mg)
Study: 23350812
Drug: Inhaled apomorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled apomorphine 0.2 mg
Study: 21080144
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metformin and fluoxetine
Study: 16584394
Drug: High-dose induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose induction (CIFN 27->9 microg daily for 24 weeks, 9 microg t.i.w. for 24 weeks) with ribavirin 800 mg/day
Study: 16584394
Drug: Low-dose treatment
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose treatment (CIFN 18 microg t.i.w. for 12 weeks, 9 microg t.i.w. for 36 weeks) with ribavirin 800 mg/day
Study: 16584394
Drug: High-dose induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose induction
Study: 16584394
Drug: Low-dose treatment
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose treatment
Study: 30545420
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy intervention (MTG), 30-45 minutes weekly sessions, average of 7 sessions
Study: 27522631
Drug: Placebo (or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (or continued low-dose spironolactone)
Study: 20171415
Drug: Pancrelipase delayed-release
Normalized name: Pancrelipase Delayed-Release Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancrelipase delayed-release 12,000-lipase unit capsules
Study: 11035615
Drug: ABVD chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABVD chemotherapy with granulocyte-colony-stimulating factor (G-CSF)
Study: 1623569
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (7.5% NaCl solution)
Study: 27709794
Drug: Sitagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (100 mg orally)
Study: 17967675
Drug: placebo (IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (IV) twice daily (n = 203)
Study: 2979239
Drug: Trimoprostil (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimoprostil (3 mg b.d.)
Study: 28764753
Drug: Complex intervention
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex intervention involving training videos and a template for conducting an individualised structured medication review.
Study: 24440473
Drug: Preoperative radiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiotherapy with concomitant chemotherapy (fluorouracil 350 mg/m² per day intravenous bolus and folinic acid 20 mg/m² per day intravenous bolus)
Study: 18353631
Drug: Preoperative radiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiotherapy with chemotherapy
Study: 24440473
Drug: Neoadjuvant radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant radiotherapy and chemotherapy
Study: 19597863
Drug: Subcutaneous TBA
Normalized name: TBA-7371
DrugBank: TBA-7371 (DB16243)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous TBA (Group A)
Study: 15362015
Drug: Reminiscence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminiscence therapy (weekly individual sessions for four months)
Study: 2252123
Drug: Three-drug sequential
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug sequential immunosuppression (Minnesota antilymphocyte globulin, prednisone, azathioprine, and cyclosporine) (n = 107)
Study: 7027747
Drug: Glucose-insulin-potassium-albumin (GIKA)
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-potassium-albumin (GIKA) infusion
Study: 7027747
Drug: 5.5% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.5% glucose infusion (Control)
Study: 31072867
Drug: Stereotactic ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy
Study: 25566977
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of piperacillin (PIPC) administered intravenously immediately after endotracheal intubation (Group A)
Study: 25566977
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of cefazolin (CEZ) administered intravenously immediately after endotracheal intubation (Group B)
Study: 19714296
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus Enzastaurin (GE); E 500 mg p.o. daily; loading-dose (1200 mg; Day 1 Cycle 1 only) and G 1000 mg/m2 i.v. Days 1, 8, and 15 in 28-day cycles
Study: 19714296
Drug: Single-agent Gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent Gemcitabine (G); G as in GE
Study: 18059013
Drug: Trachea spray
Normalized name: bovine type II collagen (tracheal cartilage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trachea spray
Study: 16824841
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg rPSGL-Ig
Study: 16824841
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg rPSGL-Ig
Study: 10685789
Drug: cA2 monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cA2 monoclonal antibody (1 mg/kg or 10 mg/kg)
Study: 10685789
Drug: cA2 monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cA2 monoclonal antibody (3 mg/kg or 10 mg/kg)
Study: 31335316
Drug: Extended 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended 16 week course of prednisolone (total dose 3150 mg/m2)
Study: 31335316
Drug: Standard 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 8 week course of prednisolone (total dose 2240 mg/m2)
Study: 16492212
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin + unmodified human insulin
Study: 14586797
Drug: Clodronate (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (300 mg intravenous infusion every 3 weeks for 2 years)
Study: 3192670
Drug: Structured play
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured play therapy approach to the child
Study: 1550076
Drug: Cyclic PAC
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic PAC chemotherapy
Study: 1550076
Drug: Brief PAC
Normalized name: PAC-113
DrugBank: PAC-113 (DB05756)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief PAC chemotherapy
Study: 8591078
Drug: FAM chemotherapy
Normalized name: fam-trastuzumab deruxtecan-nxki Injection [Enhertu]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAM chemotherapy
Study: 1550076
Drug: Cyclic PAC
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic PAC chemotherapy (Stage III or IV)
Study: 1550076
Drug: Brief PAC
Normalized name: PAC-113
DrugBank: PAC-113 (DB05756)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief PAC chemotherapy (Stage III or IV)
Study: 1550076
Drug: FAM chemotherapy
Normalized name: fam-trastuzumab deruxtecan-nxki Injection [Enhertu]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAM chemotherapy (Stage III or IV)
Study: 27714758
Drug: Ultrasound-guided fascia
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided fascia iliaca block with 2 mg.kg-1 levobupivacaine
Study: 27402726
Drug: Odanacatib 10
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib 10 mg
Study: 20238255
Drug: Initial dose
Normalized name: PEANUT ALLER INITIAL DOSE ORAL,PKT,13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose of oxytocin infusion was 0.4 IU.min(‐1)
Study: 17512704
Drug: Cefuroxime 250
Normalized name: cefuroxime 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 250 mg twice daily
Study: 2281247
Drug: GHB (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB (25 mg/kg h.s. and 3 h later)
Study: 7330791
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aminophylline and salbutamol
Study: 25001020
Drug: Dydrogesterone (oral)
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dydrogesterone (oral)
Study: 9815742
Drug: Acyclic retinoid
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclic retinoid (600 mg daily)
Study: 14976862
Drug: Guideline-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-based intervention (early echocardiography, aggressive diuretic therapy, comprehensive education, prescribed diet, intensive pharmacological therapy)
Study: 9329979
Drug: Human recombinant
Normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human recombinant growth hormone (hrGH, 6 mg/d for 2 wk)
Study: 9329979
Drug: Human recombinant
Normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human recombinant growth hormone (hrGH)
Study: 8492725
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of hydrocortisone combined with 200 mL saline
Study: 20637970
Drug: Avanafil 200
Normalized name: avanafil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avanafil 200 mg
Study: 29744791
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard antiemetic therapy without olanzapine)
Study: 22797645
Drug: 700-mg silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700-mg silymarin
Study: 20368561
Drug: Subsequent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent therapy (VMP)
Study: 20368561
Drug: Subsequent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent therapy (MP)
Study: 12455305
Drug: Lidocaine patches
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Patches]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine patches applied every 24 hours (group 1)
Study: 12455305
Drug: Lidocaine patches
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Patches]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine patches applied every 12 hours (group 2)
Study: 24393781
Drug: Robotic locomotor
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic locomotor training plus overground therapy (LKOGT) for 60 minutes, 5 days per week for 8 weeks.
Study: 15589440
Drug: Comprehensive spa
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive spa therapy program for 21 days
Study: 29447778
Drug: 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day atorvastatin
Study: 17047615
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day atorvastatin
Study: 17955648
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus TCM medication
Study: 16096518
Drug: Risperidone (0.01-0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (0.01-0.06 mg/kg/day)
Study: 26239831
Drug: High-protein breakfast
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein breakfast (HP) - 35 g protein, 1,464 kJ
Study: 26239831
Drug: Normal-protein breakfast
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-protein breakfast (NP) - 13 g protein, 1,464 kJ
Study: 9377610
Drug: Nabumetone 1500
Normalized name: Nabumetone
DrugBank: Nabumetone (DB00461)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nabumetone 1500 mg QD
Study: 10090436
Drug: Nabumetone 1000
Normalized name: nabumetone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone 1000 mg QD
Study: 7377748
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sulfadiazine (SD) 250 mg + trimethoprim (TMP) 160 mg, given twice daily for one week.
Study: 7377748
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sulfamethoxazole (SM) 800 mg + trimethoprim (TMP) 160 mg, given twice daily for one week.
Study: 21542988
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) at an initial dose of 10 ppm
Study: 18711765
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine therapy (WM)
Study: 9548155
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human FSH administered before the onset of the menstrual period (experimental group)
Study: 9548155
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (FSH administered in the early follicular phase after the onset of menses)
Study: 19210650
Drug: Tiotropium, 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium, 18 microg once daily
Study: 19210650
Drug: Salmeterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (50 microg) plus Fluticasone (200 microg), twice daily
Study: 15605005
Drug: Epinephrine injection
Normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine injection plus bipolar probe coagulation
Study: 24762631
Drug: Daily number
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily number of bowel movements
Study: 24621933
Drug: Amlodipine (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (target dose: 10 mg/d)
Study: 20148263
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of MMRV vaccine
Study: 20148263
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of MMRV vaccine
Study: 9082344
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 1000 ml 0.16 M NaCl at 16.7 ml/min for 1 hour (induced hypervolemia)
Study: 9082344
Drug: Standard conditions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard conditions (before infusion)
Study: 2049965
Drug: Intravenous or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous or oral ofloxacin
Study: 9921995
Drug: Oral ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ofloxacin
Study: 19461006
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 soft-gel pills, no active ingredients)
Study: 15657476
Drug: TCAI group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCAI group (multinutrient supplement containing TCAIs)
Study: 11697813
Drug: Short-chain fructo-oligosaccharides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-chain fructo-oligosaccharides (sc-FOSs) 10 g/day
Study: 9390050
Drug: 568 ml
Normalized name: petrolatum 568 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 568 ml (one pint) of whole or reduced fat milk per day for 18 months
Study: 9390050
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (baseline average milk intake 150 ml)
Study: 29282259
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training (6-month weekly exercise program, 60 min, two times a week)
Study: 22585232
Drug: THC 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC 7.5 mg
Study: 9379341
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus melatonin (20 mg/day orally in the evening)
Study: 11462311
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy after a 12-week period with enhanced compliance to diet and oral therapy
Study: 11462311
Drug: Enhanced compliance
Normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enhanced compliance to diet and oral therapy (control group)
Study: 9787691
Drug: Depo-testosterone (to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depo-testosterone (to boys) or conjugated estrogens (to girls) administered in 3-month blocks, alternating with placebo, at 3 dose levels.
Study: 9787691
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control group) administered in 3-month blocks, alternating with Depo-testosterone or conjugated estrogens.
Study: 1975522
Drug: Heparin in
Normalized name: heparin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin in conjunction with aspirin and a thrombolytic agent
Study: 896123
Drug: Adriamycin (20‐25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adriamycin (20‐25 mg/m2/day for three days each three weeks)
Study: 31188260
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment for intra-articular DRF based on patient factors such as younger age, clinically significant fracture displacement, normal activity level, and high-energy mechanisms.
Study: 31188260
Drug: Treatment decisions
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment decisions rated by AUC recommendations.
Study: 19140167
Drug: 5-[(123)I]IA administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-[(123)I]IA administered intravenously at approximately 0.001 microg/kg (approximately 10 mCi)
Study: 11829098
Drug: Formoterol (Oxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (Oxis Turbuhaler; 90 microg delivered dose; 120 microg metered dose)
Study: 11829098
Drug: Terbutaline (Bricanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (Bricanyl Turbuhaler; 10 mg)
Study: 2178939
Drug: Doxorubicin weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin weekly for 6 weeks followed by no further treatment (short-term regimen)
Study: 2178939
Drug: Doxorubicin weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin weekly for 6 weeks followed by monthly instillation for 2 years (long-term regimen)
Study: 72901
Drug: beta-blocker plus
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-blocker plus indomethacin (100 mg daily)
Study: 72901
Drug: beta-blocker alone
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-blocker alone (last phase)